San Diego, CA30+ days ago
ORIC's clinical stage product candidates include (1) rinzimetostat (ORIC-944), an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) enozertinib, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. The successful candidate will work closely with Technical Operations, Regulatory Affairs, and third-party Contract Development and Manufacturing Organizations (CDMOs) and will be responsible for all levels of studies, ranging from simple to complex and requires an in-depth understanding of GMPs, global Health Authority requirements, program management, quality systems, validation, and data integrity.